Login Get Started

Item added to your cart

View cart

gs-microdose-glp1-rx

Support

Terms Of Service
Privacy Policy
Medications Safety Information

Contact Us

support@humecare.com

8 The Green #24578, Dover, DE 19901

+1-(302) 262-1357

Hume Health App

Find out more about the Hume health and fitness app.

References

¹ Neeland IJ, Linge J, Birkenfeld AL. Changes in lean body mass with glucagon-like peptide-1-based therapies and mitigation strategies. Diabetes Obes Metab. 2024;26(Suppl 4):16–27. doi:10.1111/dom.15728.

² Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021;384(11):989–1002. doi:10.1056/NEJMoa2032183.

³Hume Health Corp. Lean Mass Preservation in Members: An Internal Outcomes Analysis. 2024. Hume Health Internal Study. Analysis of 8,000 premium members engaging with Pro.f insights and weighing a minimum of 3x per week; lean mass loss measured as a percentage of total weight lost via bioelectrical impedance analysis. Methodology available on request: support@humehealth.com.

⁴ Wilding JPH, Batterham RL, Davies M, et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension. Diabetes Obes Metab. 2022;24(8):1553–1564. doi:10.1111/dom.14725.

⁵ Prado CM, Phillips SM, Gonzalez MC, Heymsfield SB. Muscle matters: the effects of medically induced weight loss on skeletal muscle. Lancet Diabetes Endocrinol. 2024;12(11):785–787. doi:10.1016/S2213-8587(24)00272-9.

⁶ Ravussin E, Bogardus C. Skeletal muscle metabolism is a major determinant of resting energy expenditure. J Appl Physiol. 1989;66(3). PMID:2243122.

Choosing a selection results in a full page refresh.
Opens in a new window.